24/7 Market News Snapshot 28 May, 2025 – Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 28, 2025

DENVER, Colo., 28 May, 2025 (www.247marketnews.com) – (NASDAQ:OCUL) are discussed in this article.
Ocular Therapeutix, Inc. has experienced a notable surge in its stock, opening at $6.95 and climbing to $7.875, marking an increase of approximately 13.47%. This positive movement, bolstered by significant trading volume of 3.15 million shares, highlights robust investor interest and a favorable market sentiment surrounding the company. The previous session’s close at $6.94 reinforces today’s momentum, indicating a potentially bullish trend, although investors are advised to remain vigilant about possible resistance levels that may influence future trading decisions.

In a significant advancement for its clinical pipeline, Ocular Therapeutix has announced the imminent closure of enrollment for its SOL-R trial, which investigates AXPAXLI™, an investigational therapy targeting wet age-related macular degeneration (wet AMD). This trial represents the largest retinal tyrosine kinase inhibitor (TKI) investigation to date and has successfully enrolled over 555 participants within a year, reflecting a concerted effort from patients, investigators, and clinical sites to address the pressing need for novel treatment options.

Pravin U. Dugel, MD, the company’s Executive Chairman, President, and CEO, expressed optimism about the rapid enrollment, emphasizing the collaborative dedication to developing new standards of care for those affected by wet AMD, a leading cause of visual impairment globally. The SOL-R trial, designed following FDA protocols, aims to compare the safety and efficacy of AXPAXLI against aflibercept, with a primary goal of demonstrating non-inferiority in visual acuity by 56 weeks.

Arshad M. Khanani, MD, highlighted the anticipation within the retina community regarding AXPAXLI, which could significantly reduce treatment burdens while enhancing long-term visual outcomes. With supportive results from both the SOL-1 and SOL-R trials, Ocular Therapeutix seeks to pave the way for a regulatory submission that could reshape the management of retinal diseases, focused on improving patient care and quality of life.

Related news for (OCUL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.